[Subcutaneous and intranasal use of a LH-RH analog in the treatment of girls with central precocious puberty].
Luteinizing hormone-releasing hormone analogues (LH-RHa) offer a novel approach for non-steroidal manipulation of the reproductive endocrine axis. LH-RH agonists are now employed in the management of central precocious puberty (CPP). The aim of the present work is to show the results of one of the first experiences in our country in the therapeutics of this pathology with LH-RHa (Buserelin) both subcutaneously (SC) and intranasally (IN). Five girls with CPP, aged 1.3 to 6.8 years, were selected (Table 1). The doses employed were: 25 micrograms/kg/day in 2 SC applications followed by 1200 micrograms/day IN. In case 4 IN route only was used because she presented an allergic cutaneous reaction to the SC injection and in case 3 only the SC route was employed because of her chronological age. The period of treatment oscillated between 3 and 21 months. In 2 girls 150 mg of medroxyprogesterone was administered before the analogue therapy and it was maintained during a week. In 4 patients a regression of breast development was observed to Tanner's I or II incipient grades and in case 1 only partial involution was noted. In 4 of the 5 patients, annual growth velocity could be evaluated, showing in 3 of them a reduction between 40 and 55% VS pretreatment associated with a desacceleration of the skeletal maturation (Figs. 1, 2). The prediction of adult height increased 2 cm in one case and 4.5 cm in 2 cases; 4/5 girls showed a reduction of FSH, LH and estradiol levels to prepubertal values after 3 months of treatment and in one patient after 6 months of therapy (Fig. 3).(ABSTRACT TRUNCATED AT 250 WORDS)
Fideleff
H L
HL
Boquete
H R
HR
Azaretzky
M
M
Damilano
S
S
Cagide
A L
AL
Levalle
O
O
D000281:Administration, Intranasal; D002064:Buserelin / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007223:Infant; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood; D008525:Medroxyprogesterone / Q000627:therapeutic use; D011629:Puberty, Precocious / Q000097:blood / Q000188:drug therapy*; D012741:Sexual Maturation / Q000187:drug effects
D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008525:Medroxyprogesterone; D002064:Buserelin
Utilización de un análogo de LH-RH subcutáneo e intranasal en el tratamiento de niñas con pubertad precoz central.